DAX ®11.078,43-0,11%TecDAX ®2.580,13+0,10%S&P FUTURE2.635,90+0,15%Nasdaq 100 Future6.670,75+0,27%
finanztreff.de

DGAP-Adhoc: MOLOGEN signs license deal for China and global co-development agreement with ONCOLOGIE for lead compound lefitolimod

| Quelle: Dow Jones Newswire Web | Lesedauer etwa 4 min. | Text vorlesen Stop Pause Fortsetzen
DGAP-Ad-hoc: MOLOGEN AG / Key word(s): Contract/Agreement
MOLOGEN signs license deal for China and global co-development agreement
with ONCOLOGIE for lead compound lefitolimod

13-Feb-2018 / 16:11 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Publication of an insider information pursuant to Section 17 of the
regulation (EU) No. 596/2014

*MOLOGEN signs license deal for China and global co-development agreement
with ONCOLOGIE for lead compound lefitolimod*

Berlin, 13 February 2018 - The Executive Board of biopharmaceutical company
MOLOGEN AG (ISIN DE0006637200, SIN 663720) today announced the signing of a
license deal for the Chinese territory and a global co-development agreement
between MOLOGEN and ONCOLOGIE Inc. for its lead compound lefitolimod. The
signed agreement is conditional upon an initial payment of EUR 3 million
received by MOLOGEN. ONCOLOGIE is an oncology-focused drug development
company with headquarters in Boston, US, and operations in Shanghai. The
company is backed by top-tier international investors and has the objective
to develop novel personalized medicines in the field of immuno-oncology. The
signed agreement with ONCOLOGIE includes the development, manufacture and
commercialization of lefitolimod in China and a planned global
co-development program.

As previously announced, MOLOGEN had started negotiations on such a deal
with the Chinese iPharma. After a certain exclusivity period had expired,
MOLOGEN opened the licencing process also for additional parties.
Discussions and negotiations with ONCOLOGIE have now been successfully
completed and the deal could be signed. The terms of the signed agreement
with ONCOLOGIE define development, manufacture and commercialization of
lefitolimod in China and a planned global co-development program.

The contract comprises two parts: First, a license agreement including
sublicense rights under which MOLOGEN grants ONCOLOGIE an exclusive license
for the development, manufacturing and commercialization for MOLOGEN's lead
compound lefitolimod in the following territory: China, Hong Kong and Macao,
Taiwan and Singapore. Second, a commitment for global co-development
leveraging novel biomarker plans from ONCOLOGIE. MOLOGEN is to receive an
initial payment of EUR 3 million as well as a EUR 2 million equity
investment by ONCOLOGIE within the next 12 months.
Besides the initial payment and the equity investment, the parties agreed on
further development and commercialisation milestones. They are due upon
reaching predefined development steps as well as market approval. In
addition, commercial milestones are defined which are due upon reaching
certain sales thresholds. The total payments can amount to above EUR 100
million and will be paid over several years. Additionally, MOLOGEN will
receive low double digit royalties on sales. MOLOGEN and ONCOLOGIE will
share the economic returns from global joint development pursuant to both
parties' contributions.

All costs relating to development, registration, marketing and
commercialization of lefitolimod in the territory are to be covered by
ONCOLOGIE.

- End of the ad-hoc notification -

*Contact*

*Claudia Nickolaus*

Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

*Note about risk for future predictions*

Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation.

13-Feb-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: presse@mologen.com
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange

End of Announcement DGAP News Service

653935 13-Feb-2018 CET/CEST



(END) Dow Jones Newswires

February 13, 2018 10:11 ET ( 15:11 GMT)
Werbung

Das könnte Sie auch interessieren

Werbung

Weitere Nachrichten

Quelle: Dow Jones Newswire Web
10:44 IRW-PRESS: Cardinal Resources Limited: Cardinal -2-
10:44 IRW-PRESS: Cardinal Resources Limited: Cardinal trifft auf weiteres hochgradiges, oberflächennahes Gold bei Ndongo East
10:33 DFV Deutsche Familienversicherung AG: Auf Paris FintechForum 2019
10:33 DFV at the Paris FinTech Forum 2019
10:20 DGAP-News: Black Pearl Digital AG: Gesellschaft gibt die Aufnahme in den Primärmarkt der Börse Düsseldorf und XETRA-Notiz bekannt
10:10 DGAP-PVR: IMMOFINANZ AG: Release according to Article 135, Section 3 BörseG with the objective of Europe-wide distribution
10:10 DGAP-PVR: IMMOFINANZ AG: Veröffentlichung gemäß § 135 Abs. 3 BörseG mit dem Ziel der europaweiten Verbreitung
10:05 Deutsche Börse spielt hohe Volatilität weiter in die Hände
10:00 PTA-News: Wolfgang Steubing AG: Kommen am Rentenmarkt die Optimisten zurück? - Monatliche Anleihen-Kolumne des Asset Management Teams der Steubing AG
09:58 DGAP-PVR: HeidelbergCement AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Rubrik: Finanzmarkt
10:49 AKTIE IM FOKUS: Südzucker fallen - Warburg warnt vor weiterer Gewinnflaute
10:49 OTS: Jones Lang LaSalle SE (JLL) / Erneut breites Wachstum von Miet- und ...
10:45 IRW-News: Cardinal Resources Limited: Cardinal trifft auf weiteres hochgradiges, oberflächennahes Gold bei Ndongo East
10:40 Devisen: Euro kaum verändert
10:40 RWE: Diese Kursentwicklung überrascht
10:39 Agrarministerin Klöckner fordert schnelles Internet 'für jeden Acker'
10:32 ANALYSE-FLASH/UBS: 2018 für Ingenico schmerzlich ausgeklungen
10:26 Handelskonzern Ahold Delhaize profitiert von starkem US-Geschäft
10:24 ROUNDUP: Volkswagen bietet für drei Monate bundesweite Wechselprämie
10:20 DGAP-News: Black Pearl Digital AG: Gesellschaft gibt die Aufnahme in den Primärmarkt der Börse Düsseldorf und XETRA-Notiz bekannt (deutsch)
Werbung

News-Suche

Suchbegriff:
Werbung

Aktuelle Videos

zur Mediathek
Werbung

Werbung
Börse Stuttgart Anlegerclubschliessen
Börse Stuttgart

Wir machen Sie fit für die Börse!

Aktuelle Nachrichten, umfangreiche
Hintergrundinformationen und essentielles
Finanzwissen rund um das Thema Börse.

Jetzt kostenfrei zum Anlegerclub anmelden.
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook, Google+ oder Twitter
Aktuelle Umfrageschliessen
Immer mehr Städte führen ein Böllerverbot für Silvester ein. In Berlin sollen es nun bestimmte Straßen werden, in denen dann kein Feuerwerk mehr abgebrannt werden darf. Macht das Sinn?
Jetzt abstimmen!
Alle Umfragen ansehen